Bibliography and References

Aldurazyme® (laronidase solution for intravenous infusion only) Full Prescribing Information. BioMarin/Genzyme LLC.

Bredenkamp JK, Smith ME, Dudley JP, et al. Otolaryngologic manifestations of the mucopolysaccharidoses. Ann Otol Rhinol Laryngol. 1992;101:472-478.

Byers S, Crawley AC, Brumfield LK, et al. Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr Res. 2000;47:743-749.

Cerezyme® (imiglucerase for injection) Full Prescribing Information. Genzyme Corporation.

Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders—clinical and echocardiographic findings in 64 patients. Eur J Pediatr. 1998;157:534-538.

Data on file, BioMarin Pharmaceutical Inc.

Fabrazyme® (agalsidase beta for intravenous infusion) Full Prescribing Information. Genzyme Corporation.

Fisher A, Fox J. Newborn screening for lysosomal storage disorders [fact sheet]. National MPS Society, Inc. 2004. Available at: http://www.mpssociety.org/content/4066/Fact_Sheets/. Accessed December 17, 2004.

Fletcher J, Pamula Y, Martin AJ. Reversing respiratory disease in MPS: lessons from bone marrow transplantation. Poster accessed at www.chempathadelaide.com.au.

Fu H, Samulski RJ, McCown TJ, et al. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther. 2002;5:42-49.

Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144:574-580.

Hayflick S, Rowe S, Kavanaugh-McHugh A, et al. Acute infantile cardiomyopathy as a presenting feature of mucopolysaccharidosis VI. J Pediatr. 1992;120:269-272.

Hennig AK, Levy B, Ogilvie JM, et al. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J Neurosci. 2003;23:3302-3307.

Ho TT, Maguire AM, Aguirre GD, et al. Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. J Gene Med. 2002;4:613-621.

Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995;345:1398-1402.

Kakkis ED, Neufeld EF. The mucopolysaccharidoses. In: Berg BO, ed. Principles of Child Neurology. New York, NY: McGraw-Hill; 1996:1141-1165.

Krivit W, Pierpont ME, Ayaz K, et al. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med. 1984;311:1606-1611.

Krivit W, Whitley CB, Chang P-N, et al. Lysosomal storage diseases treated by bone marrow transplantation: review of 21 patients. In: Johnson FL, Pochedly C, eds. Bone Marrow Transplantation in Children. Pediatric Hematology/Oncology Series. New York, NY: Raven Press; 1990:261-287.

Lee V, Li CK, Shing MM, et al. Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Bone Marrow Transplant. 2000;26:455-458.

Maroteaux P, Leveque B, Marie J, Lamy M. [A new dysostosis with urinary elimination of chondroitin sulfate B]. Presse Med. 1963;71:1849-1852. French.

McGovern MM, Ludman MD, Short MP, et al. Bone marrow transplantation in Maroteaux-Lamy syndrome (MPS type 6): status 40 months after BMT. Birth Defects Orig Artic Ser. 1986;22:41-53.

Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.

Miller G, Partridge A. Mucopolysaccharidosis type VI presenting in infancy with endocardial fibroelastosis and heart failure. Pediatr Cardiol. 1983;4:61-62.

MPS I survey results: patterns in the referral, diagnosis, and management of individuals with MPS I. National MPS Society and Genzyme Corporation. April 2004. Available at: http://www.mpssociety.org/content/4010/Library/.

Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004;144(5 Suppl):S27-S34. Review.

Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol 3. 8th ed. New York, NY: McGraw-Hill; 2001:3421-3452.

Paterson DE, Harper G, Weston HJ, Mattingley J. Maroteaux-Lamy syndrome, mild form—MPS vi b. Br J Radiol. 1982;55:805-812.

Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151-156.

Resnick JM, Krivit W, Snover DC, et al. Pathology of the liver in mucopolysaccharidosis: light and electron microscopic assessment before and after bone marrow transplantation. Bone Marrow Transplant. 1992;10:273-280.

Simonaro CM, Haskins ME, Abkowitz JL, et al. Autologous transplantation of retrovirally transduced bone marrow or neonatal blood cells into cats can lead to long-term engraftment in the absence of myeloablation. Gene Ther. 1999;6:107-113.

Sjogren P, Pedersen T, Steinmetz H. Mucopolysaccharidoses and anaesthetic risks. Acta Anaesthesiol Scand. 1987;31:214-218. Review.

Smith KS, Hallett KB, Hall RK, et al. Mucopolysaccharidosis: MPS VI and associated delayed tooth eruption. Int J Oral Maxillofac Surg. 1995;24:176-180.

Spranger JW, Koch F, McKusick VA, et al. Mucopolysaccharidosis VI (Maroteaux-Lamy's disease). Helv Paediatr Acta. 1970;25:337-362.

Swiedler SJ, Beck M, Bajbouj M, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet. Forthcoming.

TKT receives fast track designation for iduronate-2-sulfatase for Hunter syndrome [press release]. Cambridge, MA: Transkaryotic Therapies, Inc.; July 15, 2004. Available at: http://www.tktx.com/newsbureau/press.htm. Accessed December 17, 2004.

Vougioukas VI, Berlis A, Kopp MV, et al. Neurosurgical interventions in children with Maroteaux- Lamy syndrome. Case report and review of the literature. Pediatr Neurosurg. 2001;35:35-38. Review.

Whitley CB. The mucopolysaccharidoses. In: Beighton P, ed. McKusick's Heritable Disorders of Connective Tissue. 5th ed. St Louis, Mo: Mosby; 1993:367-499.

Wilcox WR. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr. 2004;144(5 Suppl):S3-S14. Review.

Yaghootfam A, Schestag F, Dierks T, Gieselmann V. Recognition of arylsulfatase A and B by the UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-phosphotransferase. J Biol Chem. 2003;278:32653-32661.

Yogalingam G, Bielicki J, Hopwood JJ, Anson DS. Feline mucopolysaccharidosis type VI: correction of glycosaminoglycan storage in myoblasts by retrovirus-mediated transfer of the feline N-acetylgalactosamine 4-sulfatase gene. DNA Cell Biol. 1997;16:1189-1194.

Yogalingam G, Muller V, Hopwood JJ, Anson DS. Regulation of N-acetylgalactosamine 4- sulfatase expression in retrovirus-transduced feline mucopolysaccharidosis type VI muscle cells. DNA Cell Biol. 1999;18:187-195.